Overview
Binds to EPO receptor homodimer but signals through different pathways (JAK2/STAT vs anti-inflammatory).
Proposed mechanism
ARA-290 is a non-erythropoietic EPO derivative that activates the EPO receptor's tissue-protective (not erythropoietic) pathway, reducing inflammation and fibrosis.
What the evidence supports
Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Graded Animal
Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
ARA-290 in diabetic nephropathy
· DOI:10.2337/db15-0957 · 2016
- [2]
Non-erythropoietic EPO peptides
· DOI:10.1038/nrneph.2010.86 · 2010
- [3]
ARA-290 in diabetic nephropathy (2016)
· · 0
- [4]
Non-erythropoietic EPO peptides (2010)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.